Athira Pharma, Inc.
ATHAAthira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
No drugs found in this phase.
Frequently asked questions
When is Athira Pharma, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Athira Pharma, Inc. (ATHA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ATHA biotech catalysts?→
Add ATHA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Athira Pharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.